Circulating Oxidative Stress and Gestational Hypertension. Study of the Evolution of Free-radical Markers of Oxidative Stress From Before to After Childbirth in Two Groups of Women: Normal Pregnancy and Pre-eclampsia.
NCT ID: NCT01907620
Last Updated: 2013-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2010-11-30
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
If the hypothesis of this study turns out to be true, that is to say that women with pre-eclampsia have a higher level of oxidative stress than women with a normal pregnancy and that this difference persists after the delivery (6 months), a controlled randomized interventional study aiming to evaluate either therapeutic supplementation with antioxidant vitamins (Vit C and E) or modifications in diet could be envisaged.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia
NCT06802861
Preeclampsia and Circulating Biomarkers
NCT02136667
Molecular Study of the Maternal-fetal Interface in Preeclampsia.
NCT06232668
Prediction of Preeclampsia by Comprehensive Markers.
NCT03665623
Chronic Remote Ischemic Preconditioning as a Complement to Conventional Prenatal Care for Preeclampsia
NCT05564988
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal pregnancy
women pregnant
blood sample
pregnancy complicated by pre-eclampsia
women with pregnancy complicated by pre-eclampsia
blood sample
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood sample
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients covered by a Health Insurance scheme
* Age \> 18 years
* Normal pregnancy
* or pre-eclampsia defined according to the following classical criteria: (i) de novo hypertension defined by arterial blood pressure of at least 140 mm Hg (systolic) or at least 90 mm Hg (diastolic) confirmed by at least two measurements separated by at least 4-6 h, occurring after the 20th week of gestation in a women known beforehand to have a normal blood pressure, (ii) proteinuria defined by urinary excretion of at least 300 mg of protein per 24 h. If 24-hour urine is not available, proteinuria is defined as a concentration of urinary protein of 300 mg/L or more (or \>1 + on the urinary dip) in at least two samples of urine taken randomly, but at an interval of at least 4-6 h \[7\]. Pre-eclampsia is defined as severe if: persistent systolic BP \> 170 mm Hg and/or diastolic BP \> 110 mm Hg, and/or diuresis \< 30 ml/hour, and/or at least 2 of the following signs (headache, phosphenes, epigastric pain or vomiting, pyramidal-type patellar reflexes, papilledema, hepatic pain, thrombopenia \< 100x106 /l, ALT AST \> 70 UI/l and or hemolysis manifesting as haptoglobin \< 0.06 g/l, or a fall in LDH or the presence of schistocytes, the latter three signs define the HELLP syndrome) and/or seizures.
* Term\> 26 SA.
Exclusion Criteria
* Context of patent infection.
* Premature rupture of the fetal membranes.
* preexisting or gestational diabetes.
* Vasculoplacental diseases other than pre-eclampsia: placental abruption or infarction, intrauterine growth retardation of in utero fetal death not occurring in a context of pre-eclampsia.
* Chronic or gestational AHT not meeting the criteria for pre-eclampsia.
* Twin/multiple pregnancies
18 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Dijon
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sagot PHRC IR 2007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.